Application for listing of Roche IL-6 antibody in R & D daily was accepted by FDA / EMA

GSK terminated the clinical research of rip1 inhibitor, significantly reduced the risk of recurrence, and the application for listing Roche IL-6 antibody was accepted by FDA / EMA; after hausen, Zhengda Tianqing antiemetic drug "fosapintan" was approved; another broad-spectrum anti-cancer drug was approved in China We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel In November last year, GSK published an article in the journal cancer cells, saying that it found that another rip1 inhibitor, gsk547, could double the survival time of animals with pancreatic cancer GSK is confident to launch the phase I clinical trial of its research rip1 inhibitor gsk095, but the third quarter financial report released by GSK recently shows that due to the ongoing portfolio prioritization, the research and development of gsk095 for pancreatic cancer will be cancelled Today, sanift announced that its innovative therapy snf472 reached the primary end point in phase 2B clinical trials for patients with end-stage renal disease undergoing dialysis Coronary artery calcification levels were significantly lower in patients treated with SNF472 than in the placebo group Recently, at the International Conference on molecular targets and cancer therapeutics held in Boston, U.S., bringer Ingelheim published promising preclinical research data including bi1701963 new oral pankras inhibitors Based on these results, the compound has been introduced into phase I clinical trials, treating different types of advanced solid tumors with KRAS mutations alone and in combination with trimetazidine Today, Roche's Genentech announced that the US FDA has accepted the application for permission to use its IL-6 antibody satralizumab as a biological preparation for the treatment of adult and adolescent patients with optic neuropathic myelitis pedigree disorder At the same time, the European drug administration has also accepted satralizumab's marketing authorization application and granted it the qualification for accelerated evaluation Today, Alkermes and Bojian company jointly announced that the US FDA officially approved its new oral fumarite drug, vumerity (diroxime fumarate), for the treatment of patients with relapsing multiple sclerosis, including clinically isolated syndrome, relapsing remission disease, and active secondary progressive disease On October 30, invivoscribe, Inc announced that the European Commission has approved the drug xospata from Astaire Gamma As a single therapy, gilteritinib is used to treat adult patients with relapsed or refractory acute myeloid leukemia On October 30, Zhengda Tianqing announced that its bismeglumine for injection was approved under the trade name of Shanqi Bismeglumine is a kind of NK1 receptor antagonist It is a phosphate prodrug of arepidem After injection, it is rapidly transformed into arepidem in vivo, and then selectively combines with brain NK1 receptor through blood-brain barrier However, it has little or no affinity for 5-HT3, dopamine and corticosteroid receptor It can effectively inhibit the nausea caused by cytotoxic chemotherapy and enhance the antiemetic activity of 5-HT3 receptor antagonist ondansetron and corticosteroid dexamethasone Recently, according to the latest announcement of the drug evaluation center of the State Food and Drug Administration of China, Roche's "cancer unlimited" therapy entretinib (entretinib) capsule is intended to be developed for the treatment of locally advanced or metastatic non-small cell lung cancer with positive ros1 or locally advanced or metastatic solid tumor patients with ntrk1 / 2 / 3 gene mutation with tacit permission of clinical trials.